Positive Initial Data Analysis in POLB 001 LPS Challenge Trial
Early data read out indicates a successful LPS human challenge trial
Key Highlights
· POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
· A clear dose-response relationship was demonstrated
· Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
· Full data read-out expected in Q2 2023 following a final quality check of the unblinded data
9 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces positive initial data analysis for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the significant unmet medical need for severe influenza.
